In December 2006, a 48-year-old man presented with a 2-month history of breathlessness and chest pain. He was known to have chronic phase CML since 1997, treated initially with IFN-a. His past history was significant for two allogeneic hematopoietic SCTs (HSCTs) with PBSCs from HLA-mismatched related donors in July 2000 and June 2003, after reduced intensity conditioning with thiotepa 10 mg/kg and CY 100 mg/kg.
CSA and short-course MTX were used for GVHD prophylaxis; rabbit ATG was added to the preparative regimen for second HSCT.
The hematological response after HSCTs consisted of initial leukopenia followed by leukocytosis. Chimerism monitoring showed persistent recipient chimerism in BM and blood after both HSCTs. Karyotyping of BM metaphases showed a typical t(9;22)(q34;q11) without any other chromosome abnormalities. The P210 b3a2 BCR/ABL transcript product remained detectable at different time points after HSCTs by nested reverse transcription-PCR.
He received no further immunosuppression after the diagnosis of primary engraftment failure and did not develop any evidence of acute or chronic GVHD.
Results of cardiac and pulmonary evaluation (echocardiography, chest radiograph and pulmonary function testing) as baseline evaluation before HSCTs were within normal limits. An episode of paroxysmal supraventricular tachycardia in October 2001 was reported; systemic hypertension was ruled out.
Between the December 2001 and March 2003, the CML had been treated with targeted therapy, with imatinib. Cytogenetic resistance was observed even after the dose was increased to 800 mg daily. In April 2005, while his disease was still in chronic phase, treatment with dasatinib 70 mg twice daily was started. Because of pleural effusions (PEs) requiring thoracentesis, the dose was subsequently lowered to 50 mg twice daily in August 2006 and then to 50 mg once daily in November 2006. On admission, he was tachycardic and dyspnoeic but had no fever. He was found to have jugular venous distention, peripheral and hepatic edema, grade 3 bilateral PE according to National Cancer Institute Common Toxicity Criteria. Complete blood count was normal and human immunodeficiency virus test results were negative.
He underwent placement of a small-bore chest tube with fluid drainage: PE analysis was consistent with an exudate and showed marked lymphocyte predominance. Neither malignant cells nor bacterial growth were observed. Electrocardiography provided evidence suggestive of pulmonary arterial hypertension (PAH) by showing the right ventricular hypertrophy and right axis deviation. A diagnosis of PAH was then made upon estimation of an increased pulmonary artery systolic pressure of 49 mm Hg by transthoracic Doppler echocardiography. The left ventricular ejection fraction was normal and a mild pericardial effusion was detected. Pulmonary parenchymal involvement and thromboembolic disease were ruled out by contrast-enhanced spiral computed tomography.
Laboratory screening tests for detection of systemic rheumatic diseases, including antinuclear antibodies, antibodies to double-stranded DNA and anti-Scl-70 antibodies, were negative. A careful review of concomitant treatments ruled out concurrent administration of drugs and chemicals suspected to play a predisposing or facilitating role in the development of PAH.
Diuretics and pulse steroids were administered; dasatinib therapy was interrupted until PE recovery and resumed at 50 mg once daily in January 2007. One month later, pulmonary artery systolic pressure further increased up to 66 mm Hg. Dasatinib was permanently discontinued in June 2007 because of exertional dyspnea, liver enlargement, peripheral edema and grade 3 bilateral PE. In August 2007, a dilated right ventricle (RV) with a severely depressed ejection fraction was evidenced by cardiovascular magnetic resonance imaging (Table 1) . At the same time, a marked increase in pulmonary vascular resistance (PVR) and pulmonary artery pressure (PAP) was shown by the right heart catheterization ( Table 1 ). The cardiac index was low. Neither the PVR nor cardiac output changed after acute pharmacological challenge with i.v. adenosine and sodium nitroprussiate, suggesting a non-vasoreactive PAH. After therapy withdrawal, his clinical condition improved rapidly and the PE disappeared. In November 2007, cardiovascular magnetic resonance imaging showed normal RV volume, and the right heart catheterization evidenced a decrease in PAP and PVR (Table 1) . Normal values of the right atrial pressure, PVR, cardiac output and cardiac index were shown by a third right heart catheterization, in June 2008 (Table 1) . A mean PAP value consistent with the upper limit of normal was observed. He is presently asymptomatic with no limitations to physical activity. Throughout the course, neither anticoagulants nor licensed pulmonary vasodilatators were administered.
Pulmonary arterial hypertension is defined as a group of diseases characterized by a progressive increase of PVR (mean PAP 425 mm Hg at rest or 430 mm Hg with exercise), leading to RV failure and premature death.
The proposed causes of PAH range widely and it may be associated with connective tissue disease, congenital systemic-to-pulmonary shunts, portal hypertension, human immunodeficiency virus infection, myeloproliferative or thyroid disorders, pulmonary venous or capillary involvement, as well as a result of the use of toxic agents and anorexigens. 1, 2 Most recently, an increase in the right ventricular systolic pressure, a non invasive surrogate marker of PAP, was detected at the onset of PE in a subset of CML patients treated with dasatinib, suggesting the possibility of drugrelated PAH and subsequent subclinical heart failure. 3 Notably, the left ventricular ejection fraction remained unchanged in all patients at the time of PE. Discontinuation of dasatinib resulted in resolution of PE and a significant decrease in the right ventricular systolic pressure.
An association between dasatinib-related PE and PAH was also documented in our patient; the spontaneous improvement of PAH after treatment discontinuation suggests an etiological role of the drug in its development.
He was only taking allopurinol in addition to the dasatinib; the possibility of a drug-drug interaction as a predisposing or facilitating role in the development of PAH appears unlikely.
This case is unusual in that he had severe PAH and overt RV failure, clinical features probably related to the prolonged dasatinib treatment and long PE history. He had many adverse prognostic factors: a non-vasoreactive response and a long disease history with extensive previous treatment, including IFN-a, imatinib and HSCTs. 4 However, spontaneous improvement of PAH after treatment discontinuation was observed in November 2007, although resolution did not occur, a clinical course similar to that reported after discontinuation of other causative drugs, usually anorexigens. 5 The pathogenesis of these adverse events is still unclear, but could be related to off-target kinase inhibition, leading to pulmonary vascular smooth muscle cell changes and subsequent PVR increase. An interesting question to be answered is whether or not cytotoxic chemotherapy could have played a role in the pathogenesis of PAH or contributed to the severity of the clinical picture. 2 We therefore recommend caution with the use of dasatinib in heavily pre-treated patients, especially HSCT recipients, and suggest that estimation of the right ventricular systolic pressure and pulmonary artery systolic pressure by transthoracic Doppler echocardiography, as an excellent non-invasive screening test for PAH, should be offered to patients with PE. 
